Sans-Serramitjana Eulalia, Jorba Marta, Pedraz José Luis, Vinuesa Teresa, Viñas Miguel
Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona.
Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Vitoria, Spain.
Int J Nanomedicine. 2017 Jun 12;12:4409-4413. doi: 10.2147/IJN.S138763. eCollection 2017.
The emergence of colistin-resistant in cystic fibrosis (CF) patients, particularly after long-term inhalation treatments, has been recently reported. Nanoen-capsulation may enable preparations to overcome the limitations of conventional pharmaceutical forms. We have determined the time-dependent viability of biofilms treated with both free and nanoencapsulated colistin. We also examined the relationship between the optimal anti-biofilm activity of nanostructured lipid carrier (NLC)-colistin and the structural organization of the biofilm itself. The results showed the more rapid killing of bacterial biofilms by NLC-colistin than by free colistin. However, the two formulations did not differ in terms of the final percentages of living and dead cells, which were higher in the inner than in the outer layers of the treated biofilms. The effective anti-biofilm activity of NLC-colistin and its faster killing effect recommend further studies of its use over free colistin in the treatment of infections in CF patients.
近期有报道称，囊性纤维化（CF）患者中出现了对黏菌素耐药的情况，尤其是在长期吸入治疗之后。纳米包封或许能使制剂克服传统药物剂型的局限性。我们已经测定了用游离黏菌素和纳米包封黏菌素处理的生物膜随时间变化的活力。我们还研究了纳米结构脂质载体（NLC）-黏菌素的最佳抗生物膜活性与生物膜自身结构组织之间的关系。结果显示，NLC-黏菌素比游离黏菌素能更快地杀灭细菌生物膜。然而，两种制剂在活细胞和死细胞的最终百分比方面并无差异，在处理过的生物膜中，内层的活细胞和死细胞百分比高于外层。NLC-黏菌素有效的抗生物膜活性及其更快的杀灭效果，建议进一步研究其在治疗CF患者感染方面相较于游离黏菌素的应用。
